Anzeige
Mehr »
Login
Montag, 20.09.2021 Börsentäglich über 12.000 News von 674 internationalen Medien
Neue Rekordfahrt? Die große Chance zu Wochenbeginn!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PK7M ISIN: SE0012673291 Ticker-Symbol: MN2 
Frankfurt
20.09.21
09:10 Uhr
14,400 Euro
+0,600
+4,35 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
MENTICE AB Chart 1 Jahr
5-Tage-Chart
MENTICE AB 5-Tage-Chart
PR Newswire
252 Leser
Artikel bewerten:
(1)

Mentice receives order of total SEK 5.9 million from Baylis Medical Company

STOCKHOLM, June 30, 2021 /PRNewswire/ -- Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on interventional procedures, has entered into an agreement with Baylis Medical Company ("Baylis") to provide simulation solutions.

Based on this order, Mentice will support Baylis' product portfolio for transseptal puncture procedures with Mentice systems to be delivered in the second and third quarter of 2021.

The systems are based on the Mentice' VIST G5 platform and will support Baylis commercialization efforts to launch new medical devices in a safe and effective way by supporting clinical education.

The order will be accounted in the order book for the Medical Device Industry segment during the second quarter of 2021. The total value for the order amounts to SEK 5.9 million.

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice

Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. More information on www.mentice.com

This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person, at 11.30 on June 30, 2021.

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB, phone +46 8 528 00 399

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/mentice-ab/r/mentice-receives-order-of-total-sek-5-9-million-from-baylis-medical-company,c3376974

The following files are available for download:

https://mb.cision.com/Main/18275/3376974/1438734.pdf

Release

MENTICE-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.